⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for gemox chemotherapy

Every month we try and update this database with for gemox chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic CholangiocarcinomaNCT04961788
Intrahepatic Ch...
Gemox combimed ...
18 Years - 75 YearsShanghai Zhongshan Hospital
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsNCT04669496
Intrahepatic Ch...
PD1 Antibody
Lenvatinib
Gemox Chemother...
Neoadjuvant tre...
18 Years - 70 YearsShanghai Zhongshan Hospital
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)NCT06320301
Biliary Tract C...
Gemox Chemother...
Adebrelimab + G...
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)NCT06320301
Biliary Tract C...
Gemox Chemother...
Adebrelimab + G...
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsNCT04506281
Cholangiocarcin...
neoadjuvant tre...
18 Years - 70 YearsShanghai Zhongshan Hospital
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsNCT04506281
Cholangiocarcin...
neoadjuvant tre...
18 Years - 70 YearsShanghai Zhongshan Hospital
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsNCT04506281
Cholangiocarcin...
neoadjuvant tre...
18 Years - 70 YearsShanghai Zhongshan Hospital
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic CholangiocarcinomaNCT04361331
Cholangiocarcin...
Lenvatinib comb...
Toripalimab com...
18 Years - 75 YearsShanghai Zhongshan Hospital
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)NCT06320301
Biliary Tract C...
Gemox Chemother...
Adebrelimab + G...
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsNCT04506281
Cholangiocarcin...
neoadjuvant tre...
18 Years - 70 YearsShanghai Zhongshan Hospital
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsNCT04669496
Intrahepatic Ch...
PD1 Antibody
Lenvatinib
Gemox Chemother...
Neoadjuvant tre...
18 Years - 70 YearsShanghai Zhongshan Hospital
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: